Table 2.
Clinical outcomes classified by urokinase in unweighted and weighted study populations
| Unweighted study population | Weighted study population | |||||||
|---|---|---|---|---|---|---|---|---|
| Urokinase group (n = 67) |
Non-urokinase group (n = 27) |
p value | SMD | Urokinase group (n = 13.5) |
Non-urokinase group (n = 13.5) |
p value | SMD | |
| Composite outcome†, n (%) | 13 (19.4) | 13 (48.1) | 0.010 | 0.638 | 2.6 (19.0) | 8.1 (59.5) | 0.003 | 0.912 |
| Death during hospitalization, n (%) | 2 (3.0) | 4 (14.8) | 0.098 | 0.425 | 1.1 (8.0) | 2.4 (17.6) | 0.367 | 0.292 |
| Referral for surgery, n (%) | 11 (16.4) | 9 (33.3) | 0.125 | 0.399 | 1.5 (11.0) | 5.7 (41.9) | 0.006 | 0.747 |
†Composite outcome: death during hospitalization and referral for surgery
SMD: standardized mean difference